Skip to main content

Table 5 Genes that have a general association (P-value < 0.05) with the overall glioblastoma survival

From: Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival

Gene Symbol

Probe Identifier

P-value

Hazard Ratio1

Relevant literature references

Tgfa

205015_s_at

0.0002

0.12 (0.04-0.37)

[28]G

Sirpa

202895_s_at

<.0001

0.24 (0.14-0.41)

[26]G

Ctbp2

210835_s_at

<.0001

0.28 (0.16-0.48)

[101]O

Eef1e1

213907_at

<.0001

0.37 (0.23-0.61)

[102]O

Mapk3

212046_x_at

0.0041

0.43 (0.24-0.76)

[103]O

Actr2

200727_s_at

<.0001

0.43 (0.29-0.63)

[24]G

Igh@

211637_x_at

0.0167

0.44 (0.23-0.86)

n/a

Plcg1

216551_x_at

<.0001

0.46 (0.31-0.68)

[26]G

Mgat3

209764_at

<.0001

0.51 (0.37-0.71)

[26]G

Lrp10

201412_at

0.0041

0.60 (0.42-0.85)

[24]G

Idh1

201193_at

0.0051

0.60 (0.42-0.86)

[24]G

Tmem8b

207839_s_at

<.0001

0.60 (0.46-0.77)

n/a

Ccna2

203418_at

<.0001

0.60 (0.49-0.75)

[104]O

Topors

204071_s_at

0.0007

0.61 (0.46-0.81)

[26]G

Rpl37a

213459_at

0.0164

0.66 (0.47-0.93)

[90]G

Mdm2

217373_x_at

<.0001

0.69 (0.61-0.78)

[26]G

E2f3

203693_s_at

0.06722

0.75 (0.55-1.02)

[28]G

Mdfic

211675_s_at

0.0006

0.78 (0.68-0.90)

[105]O

Sod2

215078_at

<.0001

0.80 (0.73-0.88)

[25]G

Akr1c3

209160_at

0.0014

0.83 (0.73-0.93)

[26]G

Thbs4

204776_at

0.0007

1.18 (1.07-1.30)

[106]O

Shc3

206330_s_at

0.0031

1.32 (1.10-1.59)

[28]G

Pik3r1

212249_at

0.0145

1.34 (1.06-1.69)

[20]G

Nkx2-5

206578_at

0.0027

1.38 (1.12-1.70)

[107]O

Hras

212983_at

0.0187

1.42 (1.06-1.90)

[85]G

Bhlhb9

213709_at

0.0192

1.42 (1.06-1.92)

[108]O

C9orf95

219147_s_at

0.0004

1.43 (1.17-1.73)

[109]O

C17orf101

219254_at

0.0085

1.46 (1.10-1.94)

[110]O

Nol3

59625_at

<.0001

1.46 (1.21-1.76)

[111]O

Rangap1

212125_at

0.0225

1.47 (1.06-2.05)

[26]G

Ftsj2

222130_s_at

0.017

1.48 (1.07-2.05)

[112]O

Rrm1

201476_s_at

0.0006

1.49 (1.19-1.87)

[27]G

Jag2

209784_s_at

0.0351

1.63 (1.03-2.57)

[24]G

Tnpo1

212635_at

0.0054

1.89 (1.20-2.96)

n/a

Myo7a

211103_at

0.0033

1.97 (1.25-3.10)

[113]O

Actr2

200729_s_at

0.0001

2.18 (1.47-3.23)

[24]G

Csf1

209716_at

<.0001

2.33 (1.65-3.27)

[26]G

Ank1

208352_x_at

0.0003

2.38 (1.49-3.82)

[24]G

B3galnt1

211379_x_at

<.0001

2.40 (1.76-3.28)

[114]O

Kras

214352_s_at

0.002

2.44 (1.38-4.31)

[85]G

Ewsr1

210012_s_at

0.0005

2.49 (1.49-4.15)

[26]G

Sec24c

202361_at

<.0001

2.84 (1.76-4.60)

n/a

Rpl10l

217559_at

<.0001

2.95 (1.83-4.74)

[115]O

Ighg1

211908_x_at

0.0007

3.41 (1.68-6.93)

[116]O

Ighg1

211693_at

0.0007

4.33 (1.86-10.04)

[116]O

  1. n/a, No association with any type of cancer found in literature;
  2. 1 Hazard ratio estimate (95% confidence interval);
  3. 2 Borderline significant (P-value < 0.1) included for completeness;
  4. G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
  5. O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.